<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00114764</url>
  </required_header>
  <id_info>
    <org_study_id>20020163</org_study_id>
    <nct_id>NCT00114764</nct_id>
  </id_info>
  <brief_title>Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)</brief_title>
  <official_title>A Multicentre, Double-Blind, Randomised Phase 2 Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a single dose of pegfilgrastim is able to reduce
      the time of severe neutropenia in patients receiving induction and consolidation
      myelosuppressive chemotherapy for de novo acute myeloid leukemia similar to filgrastim.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to recover from severe neutropenia (ANC less that 0.5 X 10^9/L in chemotherapy Induction 1.</measure>
    <time_frame>Induction cycle 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of severe neutropenia during induction chemotherapy</measure>
    <time_frame>Induction cycle 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>pegfilgrastim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegfilgrastim given once after induction chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>filgrastim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Filgrastim given daily after induction chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Filgrastim given daily after induction chemotherapy</description>
    <arm_group_label>filgrastim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
    <description>Pegfilgrastim given once after induction chemotherapy</description>
    <arm_group_label>pegfilgrastim</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion

          -  Histologically confirmed de novo AML as evidenced by absence of an antecedent
             hematologic disease of &gt; 1 months duration, prior chemotherapy, prior radiation
             therapy or myelodysplastic cytogenetics (as per exclusion criteria)

          -  Life expectancy, with treatment, &gt; 3 months

          -  Age &gt; 18 years

          -  ECOG performance status 0, 1 or 2

          -  Adequate organ function to receive protocol specified chemotherapy

        Exclusion

          -  Subjects in blast transformation of chronic myeloid leukaemia (CML)

          -  Patients with secondary AML (Received previous chemotherapy or radiotherapy)

          -  Previous treatment for AML

          -  Patients with AML FAB type M3 (Acute Promyelocytic Leukemia, APL) or M7

          -  High risk (Unfavourable) cytogenetics [(-5/del(5q), -7/del(7q), t(8;21) with del (9q)
             or complex karyotype, inv(3q), abn 11q23, 20q, 21q, del(9q), t(6;9), t(9;22), abn 17p,
             complex karyotypes(&gt;3 abnormalities)]
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <results_reference>
    <citation>Sierra J, Szer J, Kassis J, Herrmann R, Lazzarino M, Thomas X, Noga SJ, Baker N, Dansey R, Bosi A. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer. 2008 Jul 10;8:195. doi: 10.1186/1471-2407-8-195.</citation>
    <PMID>18616811</PMID>
  </results_reference>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2005</study_first_submitted>
  <study_first_submitted_qc>June 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2005</study_first_posted>
  <last_update_submitted>October 30, 2008</last_update_submitted>
  <last_update_submitted_qc>October 30, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2008</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Acute myeloid leukaemia</keyword>
  <keyword>Pegfilgrastim</keyword>
  <keyword>NeulastaÂ®</keyword>
  <keyword>Neutropenia</keyword>
  <keyword>Induction chemotherapy</keyword>
  <keyword>Consolidation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

